Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !
Vai offline con l'app Player FM !
Synairgen provides update on progress during 2023
Manage episode 425897476 series 2891889
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Synairgen PLC chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the release of its full-year results. Marsden provided an overview of Synairgen's work over the past year, focusing on the development of an inhaled, broad-spectrum antiviral drug aimed at treating common respiratory viruses. He highlighted the exciting data generated from various clinical trials during the COVID-19 pandemic. Despite a decrease in hospitalisations due to current virus strains, the trials showed promising results in preventing severe outcomes in infected patients. Synairgen is now focusing on a Phase II trial for mechanically ventilated patients with severe viral lung infections. Marsden explained the rationale behind targeting this population, noting the high mortality rates and lack of antiviral therapeutic options for these patients. He also discussed the company's preparations for the trial, including lab work and collaborations with intensive care physicians. Marsden emphasised the strong commercial case for developing effective treatments in this area. Looking ahead, Synairgen is exploring funding options to support the upcoming trial, set to commence this winter. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Synairgen #ClinicalTrials #RichardMarsden #AntiviralDrug #RespiratoryViruses #Phase2Trial #COVID19 #MedicalResearch #HealthcareInnovation #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodi
Manage episode 425897476 series 2891889
Contenuto fornito da Proactive Investors. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Proactive Investors o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Synairgen PLC chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the release of its full-year results. Marsden provided an overview of Synairgen's work over the past year, focusing on the development of an inhaled, broad-spectrum antiviral drug aimed at treating common respiratory viruses. He highlighted the exciting data generated from various clinical trials during the COVID-19 pandemic. Despite a decrease in hospitalisations due to current virus strains, the trials showed promising results in preventing severe outcomes in infected patients. Synairgen is now focusing on a Phase II trial for mechanically ventilated patients with severe viral lung infections. Marsden explained the rationale behind targeting this population, noting the high mortality rates and lack of antiviral therapeutic options for these patients. He also discussed the company's preparations for the trial, including lab work and collaborations with intensive care physicians. Marsden emphasised the strong commercial case for developing effective treatments in this area. Looking ahead, Synairgen is exploring funding options to support the upcoming trial, set to commence this winter. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Synairgen #ClinicalTrials #RichardMarsden #AntiviralDrug #RespiratoryViruses #Phase2Trial #COVID19 #MedicalResearch #HealthcareInnovation #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
605 episodi
Todos os episódios
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.